Lilly is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Existing Lilly medicines are being studied to understand their potential in treating complications of COVID-19, and we're collaborating with partner companies to discover novel antibody treatments for COVID-19. Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19.
In addition, we're working with the National Institute of Allergy and Infectious Diseases (NIAID) and conducting our own randomized, double-blind, placebo-controlled clinical trial to study a JAK-inhibitor medicine as a potential treatment for certain hospitalized patients with COVID-19.
Read Lilly's COVID-19 treatment approaches chart
View CEO Dave Ricks' letter about "Lilly's principles of COVID-19 antibody therapy pricing and access"
View Lilly's neutralizing antibodies and COVID-19 fact sheet
Press Releases and Statements
bamlanivimab and etesevimab together
Lilly Cautionary Statement Regarding Forward-Looking Statements
This statement contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016), as well as baricitinib, an oral anti-inflammatory medicine, as potential treatments for patients with or at risk of infection from COVID-19 and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that studies will complete as planned, that future study results will be consistent with the results to date, that bamlanivimab, etesevimab, and baricitinib will prove to be safe and effective treatments or preventatives for COVID-19, that bamlanivimab and etesevimab will receive regulatory approvals or authorizations, that baricitinib will receive additional regulatory approvals or authorizations, or that we can provide an adequate supply of bamlanivimab, etesevimab, and baricitinib in all circumstances. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.